Patents by Inventor Hanif Ali
Hanif Ali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240343810Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.Type: ApplicationFiled: March 26, 2024Publication date: October 17, 2024Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
-
Publication number: 20240200054Abstract: The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (eg, in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (eg, produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.Type: ApplicationFiled: November 17, 2023Publication date: June 20, 2024Inventors: Allan Bradley, Hanif Ali, E-Chiang Lee
-
Publication number: 20240158502Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: November 1, 2023Publication date: May 16, 2024Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Nahida PARVEEN, Robert ROWLANDS, Gwenoline BORHIS
-
Patent number: 11920128Abstract: The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (eg, in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (eg, produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.Type: GrantFiled: July 19, 2019Date of Patent: March 5, 2024Assignee: Kymab LimitedInventors: Allan Bradley, Hanif Ali, E-Chiang Lee
-
Patent number: 11858996Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: GrantFiled: August 9, 2017Date of Patent: January 2, 2024Assignee: KYMAB LIMITEDInventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Volker Germaschewski, Ian Kirby, Miha Kosmac, Nahida Parveen, Robert Rowlands, Gwenoline Borhis
-
Publication number: 20230312720Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.Type: ApplicationFiled: September 1, 2022Publication date: October 5, 2023Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Ian KIRBY, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
-
Publication number: 20230250156Abstract: The invention relates to multimers such as multimers comprising 4 copies of a binding site or peptide; tetramers of polypeptides; and tetramers, octamers, dodecamers and hexadecamers of epitopes or effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides. The invention also relates to methods and uses to expand antigen specificity of binding sites, as well as vaccines, methods of vaccination and assay methods and reagents.Type: ApplicationFiled: March 15, 2021Publication date: August 10, 2023Inventors: Hanif ALI, Jasper CLUBE
-
Publication number: 20230192859Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.Type: ApplicationFiled: June 20, 2017Publication date: June 22, 2023Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
-
Publication number: 20230192847Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.Type: ApplicationFiled: July 15, 2022Publication date: June 22, 2023Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
-
Publication number: 20230183378Abstract: The invention relates to multimers such as tetramers of polypeptides and tetramers and octamers of effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.Type: ApplicationFiled: August 5, 2022Publication date: June 15, 2023Inventors: Hanif ALI, Terence Rabbitts, Christian Grøndahl, Jasper Clube
-
Publication number: 20220403029Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: April 22, 2022Publication date: December 22, 2022Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
-
Publication number: 20220380467Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: April 22, 2022Publication date: December 1, 2022Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
-
Patent number: 11453726Abstract: The invention relates to multimers such as tetramers of polypeptides and tetramers and octamers of effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.Type: GrantFiled: September 18, 2017Date of Patent: September 27, 2022Assignee: QUADRUCEPT BIO LIMITEDInventors: Hanif Ali, Terence Rabbitts, Christian Grøndahl, Jasper Clube
-
Patent number: 11440960Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.Type: GrantFiled: June 20, 2018Date of Patent: September 13, 2022Assignee: KYMAB LIMITEDInventors: Joana de Abreu Carvalho, Rachael Jane Kimber, Jamie Ian Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Matthew John McCourt, Richard Charles Alfred Sainson, Mohammed Hanif Ali, E-Chiang Lee, Stephen Douglas Gillies
-
Publication number: 20220162285Abstract: The invention relates to multimers such as tetramers of polypeptides; and tetramers, octamers, dodecamers and hexadecamers of epitopes or effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.Type: ApplicationFiled: March 12, 2020Publication date: May 26, 2022Inventors: Hanif ALI, Terence RABBITTS, Jasper CLUBE, Christian GRØNDAHL
-
Publication number: 20200267952Abstract: The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides. The present invention relates to multivalent (eg, multispecific) antibodies, antibody chains and polypeptides, as well as heavy chain-only antibodies (H2 antibodies) that are devoid of light chains. The invention further relates to the selection, maturation and production of these in vivo in non-human vertebrates and non-human vertebrate cells. To this end the invention also relates to such non-human vertebrates and cells. The invention also relates to the provision of means to produce and select heavy chain-only antibodies and heavy chains comprising variable domains that have undergone affinity maturation.Type: ApplicationFiled: May 7, 2020Publication date: August 27, 2020Inventors: Volker Germaschewski, E-Chiang Lee, Hanif Ali, Jasper Clube
-
Publication number: 20200190191Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.Type: ApplicationFiled: December 19, 2017Publication date: June 18, 2020Inventors: Jamie Iain CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
-
Patent number: 10667501Abstract: The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides. The present invention relates to multivalent (eg, multispecific) antibodies, antibody chains and polypeptides, as well as heavy chain-only antibodies (H2 antibodies) that are devoid of light chains. The invention further relates to the selection, maturation and production of these in vivo in non-human vertebrates and non-human vertebrate cells. To this end the invention also relates to such non-human vertebrates and cells. The invention also relates to the provision of means to produce and select heavy chain-only antibodies and heavy chains comprising variable domains that have undergone affinity maturation.Type: GrantFiled: November 17, 2014Date of Patent: June 2, 2020Assignee: Kymab LimitedInventors: Volker Germaschewski, E-Chiang Lee, Hanif Ali, Jasper Clube
-
Publication number: 20200131267Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.Type: ApplicationFiled: June 20, 2018Publication date: April 30, 2020Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
-
Publication number: 20190338274Abstract: The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (eg, in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (eg, produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.Type: ApplicationFiled: July 19, 2019Publication date: November 7, 2019Applicant: Kymab LimitedInventors: Allan Bradley, Hanif Ali, E-Chiang Lee